Get started
Author

Sven Tyge Langkjer

Observed names: Langkjer, S. T., Langkjer, Sven, Langkjer, Sven T, Langkjer, Sven Tyge, S T Langkjer, S. Langkjer, S. T. Langkjer, S.T. Langkjer, S.T.T. Langkjer, ST Langkjer, Sven Langkjer, Sven T. Langkjer
Observed institutions: Aarhus University, Roskilde Sygehus, Aalborg University Hospital, Helsinki University Hospital, Sahlgrenska University Hospital, Odense University Hospital, Herlev Hospital, Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Karolinska Institutet, University of Manchester, Vejle Sygehus, Istituti Clinici Scientifici Maugeri, Fondazione Salvatore Maugeri, Danish Breast Cancer Cooperative Group, Lillebaelt Hospital, Danish Cancer Society
ORCID: 0000-0002-5047-7523
Observed ORCID: 0000-0002-5047-7523
OpenAlex ID: A5035537863
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 599
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
2010 · Michael Andersson, Elisabeth Lidbrink, et al. · Journal of Clinical Oncology · 293
Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)
2004 · Bent Ejlertsen, Henning T. Mouridsen, et al. · Journal of Clinical Oncology · 58
Relation of Blast Cell Survival and Proliferation to Chemotherapy Resistance in Aml
1996 · Jan M. NØrgaard, Sven T. Langkjer, et al. · British Journal of Haematology · 38
MDR1 gene expression and drug resistance of AML cells
1998 · Jan Maxwell NØrgaard, Anne Bukh, et al. · British Journal of Haematology · 36
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
2018 · Marina E. Cazzaniga, Elisabetta Munzone, et al. · Advances in Therapy · 33
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
2019 · S. Delaloge, D. Cella, et al. · Annals of Oncology · 29
Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
2009 · Patricia Diana Sørensen, Erik Hugger Jakobsen, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 25
PDF
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia
2001 · Jan M. Nørgaard, Sven Tyge Langkjer, et al. · European Journal Of Haematology · 16
PDF
Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer
2020 · Anne Sofie Brems-Eskildsen, Søren Linnet, et al. · Acta Oncologica · 14
Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group
2008 · Sven T. Langkjer, Bent Ejlertsen, et al. · Acta Oncologica · 12
PDF
The NAME Trial: A Direct Comparison of Classical Oral Navelbine Versus Metronomic Navelbine in Metastatic Breast Cancer
2019 · Sven Tyge Langkjer, Julia Kenholm, et al. · Future Oncology · 9
PDF
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.
2018 · Erik Hugger Jakobsen, Dorte Nielsen, et al. · Journal of Clinical Oncology · 8
Cryopreservation of Circulating Tumor Cells for Enumeration and Characterization
2016 · Sarah Nejlund, Julie Smith, et al. · Biopreservation and Biobanking · 8
Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer
2014 · Maja Lynge Rasmussen, Gabor Liposits, et al. · Acta Oncologica · 8
PDF
Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer
2001 · Bent Ejlertsen, H.T. Mouridsen, et al. · Breast Cancer Research and Treatment · 7
Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs
1993 · Jan M. Nørgaard, Sven T. Langkjer, et al. · Leukemia Research · 7
Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients
2018 · Anne Sofie Brems-Eskildsen, Kristina Bak Kristoffersen, et al. · Acta Oncologica · 6
PDF
Susceptibility to Carcinogenic Effect of Irradiation Relationship to Age at Time of Exposure
1984 · P. Ebbesen, J. H. Villadsen, et al. · Acta Radiologica Oncology · 6
PDF
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
2018 · Anna Sofie Kappel Buhl, Troels Dreier Christensen, et al. · Breast Cancer Research and Treatment · 5
PDF
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer
2017 · Lena H. Rosvig, Sven T. Langkjer, et al. · Acta Oncologica · 5
PDF
Treatment and Treatment Considerations in a Patient with Advanced Breast Cancer and Acute Intermittent Porphyria
2006 · Charlotte Kristiansen, Sven Tyge Langkjer · Acta Oncologica · 3
PDF
Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.
2023 · Dorte Nielsen, Erik Jakobsen, et al. · Journal of Clinical Oncology · 2
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay
2019 · Troels Dreier Christensen, Anna Sofie Kappel Buhl, et al. · Breast Cancer · 2
Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer
2014 · Kamby, Claus, Tarp, Simon, et al. · 2
Works count: 63
Citation count: 1,244
H-index: 11
I10-index: 11
Year
Topic
Type